Literature DB >> 33558066

CD68-positive tumour associated macrophages, PD-L1 expression, and EBV latent infection in a high HIV-prevalent South African cohort of Hodgkin lymphoma patients.

Katherine Antel1, D Chetty2, J Oosthuizen3, Z Mohamed4, L Van der Vyver3, E Verburgh3.   

Abstract

A higher proportion of CD68-positive tumour associated macrophages (TAMs) has been associated with poorer outcomes in HIV-negative patients with Hodgkin lymphoma (HL), but whether this is true in HIV-positive patients with HL is not known. In this study, we investigated the number of CD68-positive TAMs and expression of programmed cell death-ligand 1 (PD-L1) in lymph node specimens from HL patients and correlated expression with clinical features (HIV status, disease severity and survival) and histopathological features (EBV latent positivity and subtype of HL). We stained archived lymph node specimens from 77 patients diagnosed with HL for CD68 and PD-L1. Stains were graded as: CD68 low (≤25%), CD68 high (>25%), PD-L1 low (≤50%), and PD-L1 high (>50%). Expression levels were correlated with the clinical and histopathological features using bivariate and multivariate analyses. Survival was analysed by overall and progression-free survival. Thirty-four of the 77 included patients (44%) were HIV-positive. EBV latency was detected in 97% of HIV-positive HL patients and in 14% of HIV-negative HL patients. A high CD68 score was associated with lower median haemoglobin levels (9.4 vs 11.4 g/dL; p=0.02), platelet numbers (262 vs 424 cells ×109/L; p=0.01), and lymphocyte numbers (0.99 vs 1.70 cells ×109/L, p=0.01) and a trend towards advanced disease (international prognostic score ≥4; hazard ratio 2.4; confidence interval 0.89-6.47; p=0.08). HIV status did not affect CD68 or PD-L1 expression. A higher proportion of CD68-positive TAMs was found in samples that were EBV-positive. HIV positivity and EBV negativity correlated with poorer survival. CD68 and PD-L1 expression were not predictive of survival. High CD68 expression was associated with EBV positivity but not HIV positivity and did not predict adverse outcomes. PD-L1 expression was unaffected by HIV status or EBV positivity and did predict adverse outcomes.
Copyright © 2021 Royal College of Pathologists of Australasia. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Epstein–Barr virus; HIV; Hodgkin lymphoma; South Africa; tumour associated macrophage; tumour microenvironment

Mesh:

Substances:

Year:  2021        PMID: 33558066      PMCID: PMC8292177          DOI: 10.1016/j.pathol.2020.11.004

Source DB:  PubMed          Journal:  Pathology        ISSN: 0031-3025            Impact factor:   5.335


  46 in total

1.  Frequent expression of Epstein-Barr virus latent membrane protein-1 in tumour cells of Hodgkin's disease in HIV-positive patients.

Authors:  J Audouin; J Diebold; G Pallesen
Journal:  J Pathol       Date:  1992-08       Impact factor: 7.996

Review 2.  The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape.

Authors:  Donatella Aldinucci; Annunziata Gloghini; Antonio Pinto; Rosaria De Filippi; Antonino Carbone
Journal:  J Pathol       Date:  2010-07       Impact factor: 7.996

3.  Tumor-infiltrating macrophages correlate with adverse prognosis and Epstein-Barr virus status in classical Hodgkin's lymphoma.

Authors:  Peter Kamper; Knud Bendix; Stephen Hamilton-Dutoit; Bent Honoré; Jens R Nyengaard; Francesco d'Amore
Journal:  Haematologica       Date:  2010-11-11       Impact factor: 9.941

4.  Epstein-Barr virus-associated Hodgkin's disease: epidemiologic characteristics in international data.

Authors:  S L Glaser; R J Lin; S L Stewart; R F Ambinder; R F Jarrett; P Brousset; G Pallesen; M L Gulley; G Khan; J O'Grady; M Hummel; M V Preciado; H Knecht; J K Chan; A Claviez
Journal:  Int J Cancer       Date:  1997-02-07       Impact factor: 7.396

Review 5.  The 2016 revision of the World Health Organization classification of lymphoid neoplasms.

Authors:  Steven H Swerdlow; Elias Campo; Stefano A Pileri; Nancy Lee Harris; Harald Stein; Reiner Siebert; Ranjana Advani; Michele Ghielmini; Gilles A Salles; Andrew D Zelenetz; Elaine S Jaffe
Journal:  Blood       Date:  2016-03-15       Impact factor: 22.113

6.  Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.

Authors:  Anas Younes; Ajay K Gopal; Scott E Smith; Stephen M Ansell; Joseph D Rosenblatt; Kerry J Savage; Radhakrishnan Ramchandren; Nancy L Bartlett; Bruce D Cheson; Sven de Vos; Andres Forero-Torres; Craig H Moskowitz; Joseph M Connors; Andreas Engert; Emily K Larsen; Dana A Kennedy; Eric L Sievers; Robert Chen
Journal:  J Clin Oncol       Date:  2012-03-26       Impact factor: 44.544

7.  Influence of Epstein-Barr virus genomes on patient survival in Hodgkin's disease.

Authors:  C Fellbaum; M L Hansmann; H Niedermeyer; I Kraus; M J Alavaikko; G Blanco; R Aine; R Busch; B Pütz; R Fischer
Journal:  Am J Clin Pathol       Date:  1992-09       Impact factor: 2.493

8.  CD68 tumor-associated macrophage marker is not prognostic of clinical outcome in classical Hodgkin lymphoma.

Authors:  Smita Kayal; Sandeep Mathur; Asis K Karak; Lalit Kumar; Atul Sharma; Sameer Bakhshi; Vinod Raina
Journal:  Leuk Lymphoma       Date:  2014-03-10

9.  Spindle-shaped CD163+ rosetting macrophages replace CD4+ T-cells in HIV-related classical Hodgkin lymphoma.

Authors:  Sylvia Hartmann; Christina Jakobus; Benjamin Rengstl; Claudia Döring; Sebastian Newrzela; Hans-Reinhard Brodt; Timo Wolf; Martin-Leo Hansmann
Journal:  Mod Pathol       Date:  2013-01-11       Impact factor: 7.842

10.  Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma.

Authors:  Christopher D Carey; Daniel Gusenleitner; Mikel Lipschitz; Margaretha G M Roemer; Edward C Stack; Evisa Gjini; Xihao Hu; Robert Redd; Gordon J Freeman; Donna Neuberg; F Stephen Hodi; Xiaole Shirley Liu; Margaret A Shipp; Scott J Rodig
Journal:  Blood       Date:  2017-09-11       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.